Aclaris Therapeutics Inc (NASDAQ:ACRS) – Equities researchers at Leerink Swann issued their Q1 2018 earnings estimates for shares of Aclaris Therapeutics in a research report issued on Monday. Leerink Swann analyst S. Fernandez forecasts that the biotechnology company will post earnings of ($1.06) per share for the quarter. Leerink Swann currently has a “Outperform” rating and a $54.00 price target on the stock. Leerink Swann also issued estimates for Aclaris Therapeutics’ Q2 2018 earnings at ($0.84) EPS, Q3 2018 earnings at ($1.16) EPS and Q4 2018 earnings at ($1.29) EPS.
Several other equities analysts have also issued reports on ACRS. BidaskClub raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, December 12th. Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the stock a “buy” rating in a research report on Friday, December 15th. Zacks Investment Research lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, Guggenheim started coverage on Aclaris Therapeutics in a research report on Thursday, February 8th. They issued a “buy” rating and a $53.00 price target for the company. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. Aclaris Therapeutics currently has an average rating of “Hold” and an average target price of $43.83.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.10. The company had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $0.80 million.
A number of large investors have recently modified their holdings of ACRS. Cubist Systematic Strategies LLC purchased a new position in Aclaris Therapeutics in the 3rd quarter worth about $142,000. Teacher Retirement System of Texas purchased a new position in Aclaris Therapeutics in the 4th quarter worth about $200,000. MetLife Investment Advisors LLC purchased a new position in Aclaris Therapeutics in the 4th quarter worth about $244,000. Trexquant Investment LP purchased a new position in Aclaris Therapeutics in the 3rd quarter worth about $247,000. Finally, Voya Investment Management LLC purchased a new position in Aclaris Therapeutics in the 2nd quarter worth about $247,000. 92.40% of the stock is owned by institutional investors and hedge funds.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.